Roth Capital Analysts Decrease Earnings Estimates for CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Investment analysts at Roth Capital lowered their Q3 2025 EPS estimates for Capricor Therapeutics in a research note issued on Monday, July 14th. Roth Capital analyst B. Pachaiyappan now forecasts that the biotechnology company will post earnings per share of ($0.44) for the quarter, down from their prior forecast of $1.28. Roth Capital has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. Roth Capital also issued estimates for Capricor Therapeutics' Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.85) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($1.35) EPS, Q4 2026 earnings at ($2.83) EPS and FY2026 earnings at ($3.50) EPS.

Several other equities research analysts also recently commented on the stock. Alliance Global Partners reaffirmed a "buy" rating on shares of Capricor Therapeutics in a report on Monday. HC Wainwright reissued a "buy" rating and set a $24.00 price objective (down previously from $77.00) on shares of Capricor Therapeutics in a report on Friday, July 11th. Jones Trading lowered their price target on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a report on Wednesday, June 25th. Oppenheimer reduced their price objective on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research note on Monday, June 23rd. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $22.56.

Capricor Therapeutics Stock Down 2.8%

Capricor Therapeutics stock traded down $0.20 during mid-day trading on Wednesday, reaching $7.04. 1,551,514 shares of the company's stock were exchanged, compared to its average volume of 2,093,482. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The firm has a market capitalization of $321.59 million, a PE ratio of -4.93 and a beta of 0.82. The business's fifty day simple moving average is $10.28 and its 200 day simple moving average is $11.98.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. The firm had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. During the same quarter in the prior year, the business earned ($0.31) earnings per share.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently bought and sold shares of CAPR. Summit Investment Advisors Inc. raised its stake in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after buying an additional 2,947 shares during the period. Virtus ETF Advisers LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $68,000. AlphaQuest LLC purchased a new position in Capricor Therapeutics during the 4th quarter worth approximately $78,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Capricor Therapeutics during the fourth quarter worth about $91,000. Institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.